|Description||N6-(4-Hydroxybenzyl)adenosine, an imidazopyrimidine derivative, could be effective as an inhibitor of platelet aggregation. IC50: 6.77-141 μM.|
|Synonyms||N6-(4-Hydroxybenzyl)-adenosine; 110505-75-4; N6-(4-hydroxybenzyl)adenine riboside; N6-(4-hydroxybenzyl)adenosine; CHEMBL224024; P-Topolin riboside|
|Solubility||DMSO：≥ 3.8 mg/mL|
|Application||N6-(4-Hydroxybenzyl)adenosine, an imidazopyrimidine derivative, could be effective as an inhibitor of platelet aggregation.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
MRS 2957 triethylammonium salt
MRS 2957 triethylammonium salt 7 is a selective P2Y6 receptor agonists (EC50 = 12 nM) for the treatment of muscle wasting and neurodegeneration. It exhibits 14-...
Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.
Suramin, also called as Germanin, has been demonstrated to inhibit a large variety of enzymes including urease, hexokinase, succinic dehydrogenase, p-glucuronid...
MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.
Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...
Prasugrel is a thienopyridine prodrug that is converted by esterases to a receptor antagonist for purinergic P2Y12 receptors. The blockade of P2Y12 receptor act...
MRS 2365 is a highly potent, selective P2Y1 receptor agonist (EC50 = 0.4 nM), with no activity at P2Y12 receptors and only very low agonist activity at P2Y13 re...
Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.